Drug Survival for the First TNFi in AxSpA Patients Comparing csDMARD Users to non-csDMARD Users after Propensity-Scores Adjustment
Category:
- Treatment
The Effect of Combination with a csDMARD on Drug Retention of Anti–TNF Therapy in Patients With Axial SpA
Category:
- Treatment
Decreased Incidence of Acute ATherapynterior Uveitis (AAU) in Patients on Anti-TNFalpha-
Category:
- Treatment
Efficacy of Anti-TNF-alpha-Therapy in Chronic Inflammatory Bowel Disease
Category:
- Treatment
Effect of Anti-TNFalpha-Therapy on Articular Symptoms in Crohn’s Disease
Category:
- Treatment
Efficacy of Anti-TNFalpha-Therapy in Crohn’s Disease Response (CDAI score <150 points)
Category:
- Treatment
Low but Different Incidence of Acute Inflammatory Bowel Disease (IBD) in AS Patients on Anti-TNFalpha-Therapy
Category:
- Treatment
ASAS 40 Response after 12 (16) Weeks of Treatment of Nr-axSpA Patients with TNFalpha Blocking Agents*
Category:
- Treatment
Efficacy of TNF Inhibitors in Patients with Non-radiographic Axial SpA
Category:
- Treatment
Efficacy of TNF Inhibitors According to the CRP/MRI Status at Baseline in Patients with Non-radiographic Axial SpA
Category:
- Treatment
Anti-TNFalpha-Therapy in Non-Radiographic Axial Spondyloarthritis
Category:
- Treatment
ASAS 40 Response after 12 Weeks of Treatment of Non-Radiographic Axial SpA with a TNFalpha Blocking Agent
Category:
- Treatment
ASAS40 Response to Adalimumab by Symptom Duration and Baseline CRP at Week 12 in Patients with non-radiographic axial SpA
Category:
- Treatment
ASAS40 Response to Adalimumab by Baseline MRI and CRP at Week 12 in Patients with non-radiographic axial SpA
Category:
- Treatment
ASAS 20 and ASAS 40 Responses to Golimumab at 16 Weeks in Patients with Active Non-radiographic Axial SpA
Category:
- Treatment
ASAS 40 Response to Golimumab by Baseline MRI and CRP Status at Week 16 in Active Non-radiographic Axial SpA
Category:
- Treatment
Differences in ASAS20 Response in Active Non-radiographic Axial SpA at Week 16 between Golimumab and Placebo Groups, According to Subgroups at Baseline
Category:
- Treatment
Etanercept in Early Non-radiographic Axial SpA – ASAS20, ASAS40 and ASDAS Inactive Disease Responses at Week 12
Category:
- Treatment
Etanercept in Early Non-radiographic Axial SpA – ASAS40 Responses at Week 12 Depending on Baseline MRI and CRP
Category:
- Treatment
Correlations between the C-reactive Protein Baseline Level and the Treatment Response: the Example of Etanercept in Non-radiographic Axial SpA
Category:
- Treatment
Correlations between the Baseline Severity of Inflammation in SIJs on MRI and the Treatment Response: the Example of Etanercept in Non-radiographic Axial SpA
Category:
- Treatment
Progression of Radiographic Sacroiliitis in Patients with Non-radiographic Axial Spondyloarthritis Treated with Etanercept as Compared to a Historical Control
Category:
- Treatment
Similar Response Rates in Patients with AS and with Non-Radiographic Axial SpA (nr-axSpA) after One Year of Treatment with Etanercept
Category:
- Treatment
Response Rates to Etanercept vs. Sulfasalazine Therapy over 24 weeks in Patients with Early Axial SpA (Symptom Duration <5 years)
Category:
- Treatment
Efficacy of Infliximab in Early Axial SpA (<3 years)
Category:
- Treatment
Partial Remission in Patients with Early Axial Spondyloarthritis Treated with Infliximab + Naproxen or Naproxen Alone (INFAST)
Category:
- Treatment
Maintenance of Biologic-Free Remission in Early Axial Spondyloarthritis in the INFAST Study
Category:
- Treatment
Sensitivity to Change and SMDs of Continuous Outcome Measures in Peripheral SpA (ABILITY-2)
Category:
- Treatment
Sensitivity to Change and SMDs of Continuous Outcome Measures in Peripheral SpA (TIPES)
Category:
- Treatment
PSpARC40 Response to Adalimumab at Week 12 in Active Nonpsoriatic Peripheral SpA*
Category:
- Treatment
Long-Term Response to Adalimumab in Active Nonpsoriatic Peripheral SpA*
Category:
- Treatment
Multivariate Predictors of ASDAS Inactive Disease after 1 and 3 Years of Adalimumab Exposure in Active Nonpsoriatic Peripheral SpA*
Category:
- Treatment
Multivariate Predictors of PSpARC Remission after 1 and 3 Years of Adalimumab Exposure in Active Nonpsoriatic Peripheral SpA*
Category:
- Treatment
Golimumab in Very Early Peripheral SpA*
Category:
- Treatment
Efficacy of Anti-TNF Therapy in Very Early Peripheral SpA*
Category:
- Treatment
ASAS20 and ASAS40 Response to Secukinumab at Week 16 in Patients with Ankylosing Spondylitis
Category:
- Treatment
ASAS40 Response to Secukinumab in Anti-TNF Naïve Patients and in Anti-TNF Inadequate Responders* with Ankylosing Spondylitis at Week 16
Category:
- Treatment
mSASSS Change at Week 104 in Secukinumab-treated Ankylosing Spondylitis Patients
Category:
- Treatment
ACR20-Response in Patients with Psoriatic Arthritis Treated with non-TNFi bDMARDs and tsDMARDs*
Category:
- Treatment
ACR 20-Response in Patients with Psoriatic Arthritis Treated with TNFalpha-Blockers*
Category:
- Treatment
ACR20 Response in TNFi Naïve Patients with Psoriatic Arthritis Treated with non-TNFi bDMARDs
Category:
- Treatment
ACR20 Response in TNFi Inadequate Responders with Psoriatic Arthritis Treated with non-TNFi bDMARDs
Category:
- Treatment
ACR20 Response in Patients with Psoriatic Arthritis Treated with tsDMARDs
Category:
- Treatment
Tight Control in DMARD-naive Early PsA Patients
Category:
- Treatment
Biosimilars in Axial Spondyloarthritis
Category:
- Treatment